PAR — Paradigm Biopharmaceuticals Balance Sheet
0.000.00%
- AU$155.77m
- AU$138.96m
- AU$7.11m
- 55
- 16
- 55
- 36
Annual balance sheet for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | R2023 June 30th | R2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 71.1 | 39.7 | 56.4 | 17.9 | 16.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.51 | 6.72 | 7.87 | 6.07 | 6.37 |
| Prepaid Expenses | |||||
| Total Current Assets | 81 | 47.2 | 64.8 | 25.2 | 24.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.764 | 0.571 | 0.336 | 0.19 | 0.03 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 84.8 | 50.7 | 68.1 | 28.4 | 24.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.79 | 7.83 | 13 | 3.36 | 3.23 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.52 | 8.38 | 13.4 | 3.58 | 3.39 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 78.3 | 42.3 | 54.7 | 24.8 | 21.2 |
| Total Liabilities & Shareholders' Equity | 84.8 | 50.7 | 68.1 | 28.4 | 24.6 |
| Total Common Shares Outstanding |